MENUScientific Advisory Board Judith Tam ALK Lung Cancer Research Initiative
Shirish Gadgeel, M.D. is the Division Head for Hematology/Oncology at Henry Ford Health System and a world -- renowned expert on lung cancer. He is a former University of Michigan faculty member.
Andrew Chang, M.D. is the John Alexander Distinguished Professor and Head of the Section of Thoracic Surgery at the University of Michigan. Dr. Chang's clinical interests encompass all aspects of general thoracic surgery including thoracic oncology.
Ken Culver, M.D. is an employee of ALK Positive Inc. and is currently serving as their Director of Research and Clinical Affairs. His prior experience included that of being the Oncology GlobalMedical Affairs Lead –- Cell and Gene Program at GSK, Executive Director at Novartis Oncology, and Senior Clinical Investigator at National Cancer Institute (NCI). Dr. Culver has published 2 books and more than 100 scientific articles.
Eric Fearon, M.D., Ph.D. is the Emanuel N. Maisel Professor of Oncology and Director of the Rogel Cancer Center. He is also a Professor of Human Genetics, Internal Medicine, and Pathology. The research in the Fearon laboratory seeks to address the means by which selected oncogene and tumor suppressor gene defects contribute to the development, progression and metastatic spread of colorectal cancer and to define new treatment approaches for patients with colorectal cancer.
Aaron Hata, M.D., Ph.D. is an Assistant Physician in Hematology-Oncology at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School. He works as Principal Investigator of a translational research laboratory in the MGH Center for Cancer Research, and an Investigator in the Ludwig Center for Cancer Research at Harvard. His research focuses on understanding mechanisms of tumor evolution and resistance to lung cancer targeted therapies, yielding novel therapeutic developments. Dr. Hata also serves on several multi-institutional collaborative teams focused on oncologic treatment and patient support.
Greg Kalemkerian, M.D. currently serves as the Associate Division Chief for Faculty Development and Education and the Associate Director of the Hematology/Oncology Fellowship Program in the Rogel Cancer Center. He is an internationally recognized senior lung cancer oncologist.
Andrew G. Shuman, M.D., FACS, HEC-C is an associate professor in the Department of Otolaryngology-Head and Neck Surgery at the University of Michigan Medical School. He serves as chief of the clinical ethics service in the Center for Bioethics and Social Sciences in Medicine (CBSSM).
He is internationally recognized as a thought leader in ethical issues arising within the field of otolaryngology and surgical oncology. His work involves defining the conceptual dimensions of “surgical ethics,” applying his perspective as a practicing surgeon and clinical ethicist to normative and empirical bioethics research.
Jeffrey M Sturm, M.A., M.B.A. is a tireless champion for patients diagnosed with ALK+ cancers across the globe. Jeff is a patient with ALK+ disease; he does not let his diagnosis stand in the way of enjoying his life and making a difference in the lives of many. He is an active member of ALK Positive, serving on the Research Acceleration Committee and the Clinical Trials Committee. His knowledge and stellar communication skills have been integral in connecting our initiative with biopharmaceutical companies, resulting in several collaboration agreements.
Scott Tomlins, M.D., Ph.D. is the Co-Founder, Chief Medical Officer, and Laboratory Director at Strata Oncology. He is an internationally recognized expert in the molecular pathology of cancer and precision oncology. Prior to joining Strata full time, he was an Associate Professor of Pathology and Urology at the University of Michigan Medical School and maintains an adjunct appointment in those departments.
Past Scientific Advisory Board Members
Colin Barton, D.D.S.
Alice Shaw, M.D., Ph.D.
Peter Toogood, Ph.D.